BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Feb. 20, 2002
View Archived Issues
Microscience Completes £25.5M Round, Plans Clinical Programs
LONDON - Microscience Ltd. raised £25.5 million (US$36.3 million) in a third-round funding, enabling it to put five infectious disease vaccines into clinical trials this year and develop them through to Phase IIb. (BioWorld International)
Read More
Hungarian Firm ComGenex Adds Discovery To Chemistry Services
Read More
Common Gene Links Immune System’s Generation Of Diversity
Read More
British Biotech Gains License To Cancer Drug In Phase II
Read More
Alizyme Receives Approval For Phase III Trial Of Colal-Pred
Read More
LION Streamlining Operations, Eliminating About 80 Positions
Read More
EU Commissioner Continues Push For Changes In Policy
Read More
HiberGen Raises EUR3.8M In Follow-On Funding From Trinity
Read More
Other News To Note
Read More
Oxagen, Insmed Enter Alliance On Polycystic Ovary Syndrome
Read More
Arrow Raises £7M In Second Round For Anti-Infectives Work
Read More
Australian Researchers Isolate Gene Implicated In Hay Fever
Read More
Sanofi-Synthélabo Selects Melanoma Vaccine From IDM
Read More